peoplePerson
Eunice S. Wang
Eunice Wang is an AML trialist who helped bring FLT3 and menin inhibitors to patients.
Leads leukaemia clinical research at Roswell Park; investigator on gilteritinib, quizartinib and menin inhibitor studies and NCCN AML panel member.
Role
Chief, Leukemia Service
Institution
Specialisms
Acute myeloid leukaemiaFLT3 inhibitorsNovel leukaemia agents
Profiles
| Title | Journal | Year |
|---|---|---|
| Crenolanib for FLT3-mutated AML | Blood Advances | 2021 |